Palo Alto, CA 94304
Fax: (650) 497-8959
My philosophy has always been to seek out the best possible medical therapies for a patient's disease. Even in cases where we can't provide a definitive cure, we can still assist the family and patient in other ways. I let parents know that my care team and I will walk the whole way with them.
My patients are very inspiring to me. No matter how sick they are, they always put a smile on my face. Even though I am a pediatrician, I value the bonds I form not only with the patient but with the family as a whole. My care team and I always consider the needs of the entire family when we are designing treatment approaches and actively seek ways to reduce the burden on a family caring for a chronically ill child.
New York Medical College Registrar, Valhalla, NY, 5/31/1998
United States Naval Medical Center San Diego Pediatric Residency, San Diego, CA, 06/30/2003
Stanford University Pediatric Hematology Oncology Fellowship, Palo Alto, CA, 6/30/2009
Pediatric Hematology-Oncology, American Board of Pediatrics
View details for Web of Science ID 000639851600094
View details for DOI 10.1200/JCO.2021.39.6_suppl.TPS390
View details for Web of Science ID 000636801500039
View details for Web of Science ID 000790145400326
View details for DOI 10.1111/jth.13895
View details for Web of Science ID 000419402000023
View details for PubMedID 29178421
View details for DOI 10.12788/jcso.0290
View details for Web of Science ID 000398367400004
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and primary cutaneous gamma delta T-cell lymphoma (PCGD-TCL) were initially both classified as subcutaneous panniculitis-like T-cell lymphoma. In 2008, SPTCL with alpha-beta T-cell receptor subtype was separated from primary cutaneous gamma delta T-cell lymphomas (PCGD-TCL). We report four pediatric cases that demonstrate the heterogeneity of each disease and show that PCGD-TCL in children can have an indolent course, whereas SPTCL can behave aggressively. Three patients had spontaneous, durable remissions without treatment, whereas the one patient with disease progression was treated successfully. Watchful waiting may thus be appropriate for initial management of children.
View details for DOI 10.1002/pbc.25626
View details for PubMedID 26146844
View details for DOI 10.1371/journal.pgen.1003464
View details for PubMedID 23637631
Hereditary hemochromatosis (HH) is an autosomal-recessive disorder of iron metabolism that most commonly manifests in the fourth or fifth decade of life. Here, we describe a 14-year-old male who presented with high-risk acute lymphoblastic leukemia and previously undiagnosed HH. His treatment course was remarkable for significant therapeutic complications, including iron overload, hepatic failure, cardiac dysfunction, and death. Postmortem testing revealed homozygosity for the C282Y mutation, confirming the diagnosis of HH. Since HH mutations occur commonly in select populations, screening patients with leukemia for HH may better inform treatment decisions regarding chemotherapy, transfusions, and/or iron chelation therapy.
View details for DOI 10.1002/pbc.22829
View details for Web of Science ID 000297641300020
View details for PubMedID 22076832
We report 4 patients who developed hyperphosphatemia while receiving liposomal amphotericin B to treat an invasive fungal infection. Resolution of the hyperphosphatemia occurred after transition to amphotericin B lipid complex. This phenomenon may occur more commonly in patients with mild to moderate renal insufficiency.
View details for DOI 10.1097/INF.0b013e31815922a3
View details for PubMedID 18162947